TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07483827: A Phase 1 First-in-Human Clinical Trial in Healthy Participants and Patients With C3-Glomerulopathy to Assess Safety, Tolerability, and Pharmacokinetics of CPV-104

Sponsor: eleva GmbH · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 39 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$270,912

Rescue Site Savings

+$180,608

Unlock Full NCT07483827 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07483827 Rescue Dossier →